[SCHEDULE 13G/A] Pulmonx Corporation SEC Filing

Rhea-AI Filing Summary

FMR LLC and Abigail P. Johnson report beneficial ownership of 2,179,993.02 shares of Pulmonx Corp common stock, representing 5.4% of the outstanding class. FMR LLC is shown with sole voting power over 2,175,878 shares and sole dispositive power over 2,179,993.02 shares; Abigail P. Johnson is reported with sole dispositive power over 2,179,993.02 shares and no voting power. The filing states the shares are held in the ordinary course of business and were not acquired to change or influence control of the issuer.

The filing refers to an accompanying Exhibit 99 and incorporates prior powers of attorney by reference. No other person is identified as holding more than 5% of the common stock.

Positive

• Material disclosure of a 5.4% stake in Pulmonx Corp provides transparency to the market
• Clear allocation of voting and dispositive powers (2,175,878 voting; 2,179,993.02 dispositive) enables precise reconciliation
• Statement that shares are held in the ordinary course and not to influence control clarifies filing intent
• References to Exhibit 99 and prior powers of attorney provide supporting documentation and authority

Negative

• None.

Insights

Financial Analyst

TL;DR: FMR LLC and Abigail Johnson disclose a material, but passive, 5.4% stake in Pulmonx; voting and dispositive powers are clearly allocated.

The disclosure shows a meaningful single-party stake of 5.4%, large enough to be noticed by investors but presented as passive and held in the ordinary course of business. The split between voting power (2,175,878) and dispositive power (2,179,993.02) is specific, enabling precise share-count reconciliation. The filing's explicit statement that the shares were not acquired to influence control reduces immediate governance concerns, though market participants may monitor for future amendments or Schedule 13D activity.

Corporate Governance Expert

TL;DR: This is a routine, compliant Schedule 13G/A showing passive beneficial ownership with clear power attributions and referenced exhibits.

The filing adheres to disclosure norms by specifying voting/dispositive powers and confirming ordinary-course holding. Referencing Exhibit 99 and prior powers of attorney provides traceability for authority to sign. Because the filing declares no intent to influence control, it classifies as passive ownership under the rules; governance impact is therefore limited unless future filings indicate an active intent.

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

SCHEDULE 13G

UNDER THE SECURITIES EXCHANGE ACT OF 1934

(Amendment No. 5)

PULMONX CORP

(Name of Issuer)

COMMON STOCK

(Title of Class of Securities)

745848101

(CUSIP Number)

08/29/2025

(Date of Event Which Requires Filing of this Statement)

Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

Rule 13d-1(b)

Rule 13d-1(c)

Rule 13d-1(d)

SCHEDULE 13G

CUSIP No. 745848101

1

Names of Reporting Persons

FMR LLC

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

DELAWARE

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 2,175,878.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,179,993.02
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,179,993.02

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

HC

SCHEDULE 13G

CUSIP No. 745848101

1

Names of Reporting Persons

Abigail P. Johnson

2

Check the appropriate box if a member of a Group (see instructions)

(a)
(b)

3

Sec Use Only

4

Citizenship or Place of Organization

UNITED STATES

Number of Shares Beneficially Owned by Each Reporting Person With:

5	Sole Voting Power 0.00
6	Shared Voting Power 0.00
7	Sole Dispositive Power 2,179,993.02
8	Shared Dispositive Power 0.00

9

Aggregate Amount Beneficially Owned by Each Reporting Person

2,179,993.02

10

Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

11

Percent of class represented by amount in row (9)

5.4 %

12

Type of Reporting Person (See Instructions)

IN

SCHEDULE 13G

Item 1.
(a)	Name of issuer: PULMONX CORP
(b)	Address of issuer's principal executive offices: 700 CHESAPEAKE DRIVE,REDWOOD CITY,CA,US,94063
Item 2.
(a)	Name of person filing: FMR LLC
(b)	Address or principal business office or, if none, residence: 245 Summer Street, Boston, Massachusetts 02210
(c)	Citizenship: Not applicable
(d)	Title of class of securities: COMMON STOCK
(e)	CUSIP No.: 745848101
Item 3.	If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
(a)	Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
(b)	Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
(c)	Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
(d)	Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
(e)	An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
(f)	An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
(g)	A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
(h)	A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
(i)	A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
(j)	A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J), please specify the type of institution:
(k)	Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
Item 4.	Ownership
(a)	Amount beneficially owned: 2179993.02
(b)	Percent of class: 5.4 %
(c)	Number of shares as to which the person has:
	(i) Sole power to vote or to direct the vote: Please see the responses to Items 5 and 6 on the cover page.
	(ii) Shared power to vote or to direct the vote: 0.00
	(iii) Sole power to dispose or to direct the disposition of: 2179993.02
	(iv) Shared power to dispose or to direct the disposition of: 0.00
Item 5.	Ownership of 5 Percent or Less of a Class.
Item 6.	Ownership of more than 5 Percent on Behalf of Another Person.
	If any other person is known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, such securities, a statement to that effect should be included in response to this item and, if such interest relates to more than 5 percent of the class, such person should be identified. A listing of the shareholders of an investment company registered under the Investment Company Act of 1940 or the beneficiaries of employee benefit plan, pension fund or endowment fund is not required. One or more other persons are known to have the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, the COMMON STOCK of PULMONX CORP. No one other person's interest in the COMMON STOCK of PULMONX CORP is more than five percent of the total outstanding COMMON STOCK.
Item 7.	Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
	If a parent holding company has filed this schedule, pursuant to Rule 13d-1(b)(ii)(G), so indicate under Item 3(g) and attach an exhibit stating the identity and the Item 3 classification of the relevant subsidiary. If a parent holding company has filed this schedule pursuant to Rule 13d-1(c) or Rule 13d-1(d), attach an exhibit stating the identification of the relevant subsidiary. See attached Exhibit 99.
Item 8.	Identification and Classification of Members of the Group.
	Not Applicable
Item 9.	Notice of Dissolution of Group.
	Not Applicable

Item 10.

Certifications:

By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

SIGNATURE

After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

FMR LLC

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 3, 2023, by and on behalf of FMR LLC and its direct and indirect subsidiaries*
Date:	09/05/2025

Abigail P. Johnson

Signature:	Stephanie J. Brown
Name/Title:	Duly authorized under Power of Attorney effective as of January 26, 2023, by and on behalf of Abigail P. Johnson**
Date:	09/05/2025

Comments accompanying signature: * This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 10, 2023, accession number: 0000315066-23-000003. ** This power of attorney is incorporated herein by reference to Exhibit 24 to the Schedule 13G filed by FMR LLC on January 31, 2023, accession number: 0000315066-23-000038.

Exhibit Information

Please see Exhibit 99 for 13d-1(k) (1) agreement.

FAQ

How many Pulmonx (LUNG) shares do FMR LLC and Abigail P. Johnson report owning?

They report beneficial ownership of 2,179,993.02 shares, representing 5.4% of the class.

What voting and dispositive powers are reported for FMR LLC in this filing?

FMR LLC reports sole voting power over 2,175,878 shares and sole dispositive power over 2,179,993.02 shares.

Does Abigail P. Johnson have voting power over the reported shares?

The filing reports Abigail P. Johnson has no voting power and sole dispositive power over 2,179,993.02 shares.

Is the reported ownership intended to influence control of Pulmonx?

No; the filing explicitly states the securities are held in the ordinary course of business and not to change or influence control of the issuer.

Does the filing identify any other person with more than 5% ownership?

No. The filing states no other person's interest exceeds 5% of Pulmonx common stock.